Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: StocksDATsoar who wrote (54805)	7/17/2000 12:45:09 AM
From: Jim Bishop	Respond to of 150070

CLYC here's an interesting post on RB: ragingbull.altavista.com By: genomic1 $ Reply To: 314 by MamboMerchant $$$ Sunday, 16 Jul 2000 at 11:46 PM EDT Post # of 325 MM--I disagree with your statement that this technology is easily duplicated. First of all, I am assuming that when you say "technology" that you are referring to DNAPrint Genomic's "platform". As you may know, up to now all efforts in this area have gone mostly to help create a reference DNA (the human genome project) which has taken billions of dollars and is the equivalent of putting a man on the moon. Now that it is nearing completion, the next big application will be the interpretation of how genetic diversity affects the efficacy and side effects of drugs (a field called "personalized medicine"). Most studies so far that have been looking into the genetic basis for disease have focused on a defect in a single gene (ie. breast cancer-BRCA1 gene or sickle-cell anemia). However, most diseases are not single gene defects but are the result of complex interactions between several genes (these multi-gene defects are where DNAPrint Genomics is concentrating). Now, why are most all companies avoiding concentrating on diseases caused by multigenetic interactions???? Here is why..... in order to identify these different genes one must have access to sophisticated algorithms and software with fuzzy logic neural net design that can recognize the patterns among hundreds of thousands of genes that make one susceptible to a disease or make one a positive/negative receptor to a drug. This takes more than just a bunch of scientists in a lab, but a "dream team" with a skill set that combines knowledge of software programming, statistics, novel math modeling techniques, and molecular genetics. Currently, no other company that I know of exists that has these attributes. Now, will other companies eventually hire the people that have these skills? Well, I would guess that they would, but if you check with human resources at the big genomic companies now you will find few soliciting for high-level mathematicians. Note: first mover advantage is extremely valuable in this field. Why? Because you can patent these "solutions" if they have utility. One final question: What is a patent worth on the gene that determines cancer?